548
Views
9
CrossRef citations to date
0
Altmetric
Review

Exploring the clinical relevance of cough hypersensitivity syndrome

ORCID Icon & ORCID Icon
Pages 275-284 | Received 18 Nov 2019, Accepted 06 Jan 2020, Published online: 15 Jan 2020

References

  • Irwin RS, Corrao WM, Pratter MR. Chronic persistent cough in the adult: the spectrum and frequency of causes and successful outcome of specific therapy. Am Rev Respir Dis. 1981 Apr;123(4 Pt 1):413–417.
  • Voorsanger WC, Firestone F. Etiological factors in chronic cough: an analysis of one hundred cases-preliminary report. Cal West Med. 1927 Jan;26(1):48–50.
  • Phillips AM, Phillips RW, Thompson JL. Chronic cough: analysis of etiologic factors in a survey of 1,274 men. Ann Intern Med. 1956 Aug;45(2):216–231.
  • Chung KF, Pavord ID. Prevalence, pathogenesis, and causes of chronic cough. Lancet. 2008 Apr 19;371(9621):1364–1374.
  • McGarvey L. The difficult-to-treat, therapy-resistant cough: why are current cough treatments not working and what can we do? Pulm Pharmacol Ther. 2013;26(5):528–531.
  • Hulme K, Dogan S, Parker SM, et al. ‘Chronic cough, cause unknown’: a qualitative study of patient perspectives of chronic refractory cough. J Health Psychol. 2019;24(6):707–716.
  • Morice AH. The cough hypersensitivity syndrome: a novel paradigm for understanding cough. Lung. 2010 Jan;188(Suppl 1):S87–S90.
  • Chung KF. Chronic ‘cough hypersensitivity syndrome’: a more precise label for chronic cough. Pulm Pharmacol Ther. 2011 Jun;24(3):267–271.
  • Morice AH, Fontana GA, Sovijarvi AR, et al. The diagnosis and management of chronic cough. Eur Respir J. 2004 Sep;24(3):481–492.
  • Irwin RS, French CL, Chang AB, et al. Classification of cough as a symptom in adults and management algorithms: CHEST guideline and expert panel report. Chest. 2018;153(1):196–209.
  • Morice AH, Millqvist E, Belvisi MG, et al. Expert opinion on the cough hypersensitivity syndrome in respiratory medicine. Eur Respir J. 2014 Nov;44(5):1132–1148.
  • Song WJ, Chang YS, Faruqi S, et al. The global epidemiology of chronic cough in adults: a systematic review and meta-analysis. Eur Respir J. 2015 May;45(5):1479–1481.
  • Song WJ, Chang YS, Faruqi S, et al. Defining chronic cough: a systematic review of the epidemiological literature. Allergy Asthma Immunol Res. 2016 Mar;8(2):146–155.
  • French CL, Irwin RS, Curley FJ, et al. Impact of chronic cough on quality of life. Arch Intern Med. 1998 Aug 10–24;158(15):1657–1661.
  • Hilton E, Marsden P, Thurston A, et al. Clinical features of the urge-to-cough in patients with chronic cough. Respir Med. 2015 Jun;109(6):701–707.
  • Won HK, Kang SY, Kang Y, et al. Cough-related Laryngeal sensations and triggers in adults with chronic cough: symptom profile and impact. Allergy Asthma Immunol Res. 2019 Sep;11(5):622–631.
  • Vertigan AE, Theodoros DG, Gibson PG, et al. Efficacy of speech pathology management for chronic cough: a randomised placebo controlled trial of treatment efficacy. Thorax. 2006 Dec;61(12):1065–1069.
  • Morice AH, Menon MS, Mulrennan SA, et al. Opiate therapy in chronic cough. Am J Respir Crit Care Med. 2007 Feb 15;175(4):312–315.
  • Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012 Nov 3;380(9853):1583–1589.
  • Abdulqawi R, Dockry R, Holt K, et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2015 Mar 28;385(9974):1198–1205.
  • Vertigan AE, Kapela SL, Ryan NM, et al. Pregabalin and speech pathology combination therapy for refractory chronic cough: a randomized controlled trial. Chest. 2016 Mar;149(3):639–648.
  • Chamberlain Mitchell SA, Garrod R, Clark L, et al. Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: a multicentre randomised control trial. Thorax. 2017 Feb;72(2):129–136.
  • Song WJ, Morice AH. Cough hypersensitivity syndrome: a few more steps forward. Allergy Asthma Immunol Res. 2017. 9. Sep(5):394–402.
  • Liu Q, Fujimura M, Tachibana H, et al. Characterization of increased cough sensitivity after antigen challenge in guinea pigs. Clin Exp Allergy. 2001 Mar;31(3):474–484.
  • Tatar M, Plevkova J, Brozmanova M, et al. Mechanisms of the cough associated with rhinosinusitis. Pulm Pharmacol Ther. 2009 Apr;22(2):121–126.
  • Lieu TM, Myers AC, Meeker S, et al. TRPV1 induction in airway vagal low-threshold mechanosensory neurons by allergen challenge and neurotrophic factors. Am J Physiol Lung Cell Mol Physiol. 2012 May 1;302(9):L941–L948.
  • Zaccone EJ, Lieu T, Muroi Y, et al. Parainfluenza 3-induced cough hypersensitivity in the Guinea Pig Airways. PLoS One. 2016;11(5):e0155526.
  • Kollarik M, Brozmanova M. Cough and gastroesophageal reflux: insights from animal models. Pulm Pharmacol Ther. 2009 Apr;22(2):130–134.
  • Belvisi MG, Birrell MA, Khalid S, et al. Neurophenotypes in airway diseases. Insights from translational cough studies. Am J Respir Crit Care Med. 2016 Jun 15;193(12):1364–1372.
  • Fang Z, Huang C, Zhang JJ, et al. Traffic-related air pollution induces non-allergic eosinophilic airway inflammation and cough hypersensitivity in guinea-pigs. Clin Exp Allergy. 2019 Mar;49(3):366–377.
  • Deng Z, Zhou W, Sun J, et al. IFN-γ enhances the cough reflex sensitivity via calcium influx in vagal sensory neurons. Am J Respir Crit Care Med. 2018;198(7):868–879.
  • Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016 Feb;47(2):410–419.
  • Hilton EC, Baverel PG, Woodcock A, et al. Pharmacodynamic modeling of cough responses to capsaicin inhalation calls into question the utility of the C5 end point. J Allergy Clin Immunol. 2013;132(4):847–855. e5.
  • Cho PS, Fletcher HV, Turner RD, et al. Impaired cough suppression in chronic refractory cough. Eur Respir J. 2019;53(5):1802203.
  • Ando A, Smallwood D, McMahon M, et al. Neural correlates of cough hypersensitivity in humans: evidence for central sensitisation and dysfunctional inhibitory control. Thorax. 2016 Apr;71(4):323–329.
  • Prudon B, Birring SS, Vara DD, et al. Cough and glottic-stop reflex sensitivity in health and disease. Chest. 2005 Feb;127(2):550–557.
  • Fowles HE, Rowland T, Wright C, et al. Tussive challenge with ATP and AMP: does it reveal cough hypersensitivity? Eur Respir J. 2017;49(2):1601452.
  • Morice AH, Fontana GA, Belvisi MG, et al. ERS guidelines on the assessment of cough. Eur Respir J. 2007 Jun;29(6):1256–1276.
  • Birring SS, Spinou A. How best to measure cough clinically. Curr Opin Pharmacol. 2015;22:37–40.
  • Vertigan AE, Bone SL, Gibson PG. Development and validation of the Newcastle laryngeal hypersensitivity questionnaire. Cough. 2014;10(1):1.
  • La-Crette J, Lee K, Chamberlain S, et al. The development of a cough hypersensitivity questionnaire (CHQ). Thorax. 2012;67(Suppl 2):A127–A127.
  • Sinha A, Lee KK, Rafferty GF, et al. Predictors of objective cough frequency in pulmonary sarcoidosis. Eur Respir J. 2016 May;47(5):1461–1471.
  • Muccino D, Green S. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough. Pulm Pharmacol Ther. 2019;56:75–78.
  • Morice AH, Kitt MM, Ford AP, et al. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study. Eur Respir J. 2019 Jul;54(1):1900439.
  • Mazzone SB, Chung KF, McGarvey L. The heterogeneity of chronic cough: a case for endotypes of cough hypersensitivity. Lancet Respir Med. 2018;6(8):636–646.
  • Martinez F, Afzal A, Kitt M, et al. The treatment of chronic cough in idiopathic pulmonary fibrosis patients with Gefapixant, a P2x3 receptor antagonist. American Thoracic Society; 2019.
  • Birring SS, Wijsenbeek MS, Agrawal S, et al. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial. Lancet Respir Med. 2017 Oct;5(10):806–815.
  • Morice AH, Millqvist E, Bieksiene K, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020 Jan 2; 55 (i):p101136.
  • Song WJ, Won HK, An J, et al. Chronic cough in the elderly. Pulm Pharmacol Ther. 2019;56:63–68.
  • Kahrilas PJ, Howden CW, Hughes N, et al. Response of chronic cough to acid-suppressive therapy in patients with gastroesophageal reflux disease. Chest. 2013 Mar;143(3):605–612.
  • Lee SE, Lee JH, Kim HJ, et al. Inhaled corticosteroids and placebo treatment effects in adult patients with cough: a systematic review and meta-analysis. Allergy Asthma Immunol Res. 2019;Nov;11(6):856–870.
  • Undem BJ, Taylor-Clark T. Mechanisms underlying the neuronal-based symptoms of allergy. J Allergy Clin Immunol. 2014 Jun;133(6):1521–1534.
  • Song DJ, Song WJ, Kwon JW, et al. KAAACI evidence-based clinical practice guidelines for chronic cough in adults and children in Korea. Allergy Asthma Immunol Res. 2018 Nov;10(6):591–613.
  • Gibson P, Denburg J, Dolovich J, et al. Chronic cough: eosinophilic bronchitis without asthma. Lancet. 1989;333(8651):1346–1348.
  • Morice AH, Kastelik JA. Cough. 1: chronic cough in adults. Thorax. 2003 Oct;58(10):901–907.
  • Djukanovic R, Sterk PJ, Fahy JV, et al. Standardised methodology of sputum induction and processing. Eur Respir J Suppl. 2002;37:1s–2s.
  • Korevaar DA, Westerhof GA, Wang J, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. Lancet Respir Med. 2015 Apr;3(4):290–300.
  • Price DB, Buhl R, Chan A, et al. Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. Lancet Respir Med. 2018;6(1):29–39.
  • Wagener AH, de Nijs SB, Lutter R, et al. External validation of blood eosinophils, FENO and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70(2):115–120.
  • Song W-J, Kim HJ, Shim J-S, et al. Diagnostic accuracy of fractional exhaled nitric oxide measurement in predicting cough-variant asthma and eosinophilic bronchitis in adults with chronic cough: a systematic review and meta-analysis. J Allergy Clin Immunol. 2017;140(3):701–709.
  • Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005 Nov;26(5):948–968.
  • Smith JA, McGarvey L, Morice AH, et al. The effect of aclidinium on symptoms including cough in COPD: a phase IV, doubleblind, placebo-controlled, parallel-group study. Am J Respir Crit Care Med. 2019;200:642-645.
  • Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003 Feb 8;361(9356):449–456.
  • Irwin RS, French CT, Smyrnios NA, et al. Interpretation of positive results of a methacholine inhalation challenge and 1 week of inhaled bronchodilator use in diagnosing and treating cough-variant asthma. Arch Intern Med. 1997;157(17):1981–1987.
  • Satia I, Tsamandouras N, Holt K, et al. Capsaicin-evoked cough responses in asthmatic patients: evidence for airway neuronal dysfunction. J Allergy Clin Immunol. 2017 Mar;139(3):771–779 e10.
  • Plevkova J, Song WJ. Chronic cough in subjects with upper airway diseases - analysis of mechanisms and clinical applications. Asia Pac Allergy. 2013 Apr;3(2):127–135.
  • Lilienfield LS, Rose JC, Princiotto JV. Antitussive activity of diphenhydramine in chronic cough. Clin Pharmacol Ther. 1976 Apr;19(4):421–425.
  • Fujimori K, Suzuki E, Arakawa M. Effects of oxatomide, H1-antagonist, on postinfectious chronic cough; a comparison of oxatomide combined with dextromethorphan versus dextromethorphan alone. Arerugi. 1998 Jan;47(1):48–53.
  • Baena-Cagnani CE, Berger WE, DuBuske LM, et al. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of β2-agonists in patients with seasonal allergic rhinitis and asthma [Article]. Int Arch Allergy Immunol. 2003;130(4):307–313.
  • Berger WE, Schenkel EJ, Mansfield LE. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol. 2002 Nov;89(5):485–491.
  • Iwata T, Ito I, Niimi A, et al. Mechanical stimulation by postnasal drip evokes cough. PLoS One. 2015;10(11):e0141823.
  • O’Hara J, Jones N. Post-nasal drip syndrome”: most patients with purulent nasal secretions do not complain of chronic cough. Rhinology. 2006;44(4):270–273.
  • Lim KG, Rank MA, Kita H, et al. Neuropeptide levels in nasal secretions from patients with and without chronic cough. Ann Allergy Asthma Immunol. 2011;107(4):360–363.
  • Bucher S, Schmid-Grendelmeier P, Soyka MB. Altered viscosity of nasal secretions in postnasal drip. Chest. 2019 Oct;156(4):659–666.
  • Kahrilas PJ, Altman KW, Chang AB, et al. Chronic cough due to gastroesophageal reflux in adults: CHEST guideline and expert panel report. Chest. 2016 Dec;150(6):1341–1360.
  • Badri H, Satia I, Woodcock A, et al. The usefulness of heartburn as a marker of the success of acid suppression therapy in chronic cough. Am J Respir Crit Care Med. 2015;191:1.
  • Patterson N, Mainie I, Rafferty G, et al. Nonacid reflux episodes reaching the pharynx are important factors associated with cough. J Clin Gastroenterol. 2009 May-Jun;43(5):414–419.
  • Burke JM, Jackson W, Morice AH. The role of high resolution oesophageal manometry in occult respiratory symptoms. Respir Med. 2018 May;138:47–49.
  • Xu X-H, Yang Z-M, Chen Q, et al. Therapeutic efficacy of baclofen in refractory gastroesophageal reflux-induced chronic cough. World J Gastroenterol. 2013;19(27):4386.
  • Xu X, Lv H, Yu L, et al. A stepwise protocol for the treatment of refractory gastroesophageal reflux-induced chronic cough. J Thorac Dis. 2016;8(1):178.
  • Berkhof FF, Doornewaard-ten Hertog NE, Uil SM, et al. Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respir Res. 2013 Nov;14(14):125.
  • Smith JE, Morjaria JB, Morice AH. Dietary intervention in the treatment of patients with cough and symptoms suggestive of airways reflux as determined by Hull airways Reflux Questionnaire. Cough. 2013;9(1):27.
  • Vertigan AE, Gibson PG. Chronic refractory cough as a sensory neuropathy: evidence from a reinterpretation of cough triggers. J Voice. 2011;25(5):596–601.
  • Vertigan AE, Kapela SM, Kearney EK, et al. Laryngeal dysfunction in cough hypersensitivity syndrome: a cross-sectional observational study. J Allergy Clin Immunol Pract. 2018 Nov - Dec;6(6):2087–2095.
  • Lee B, Woo P. Chronic cough as a sign of laryngeal sensory neuropathy: diagnosis and treatment. Ann Otol Rhinol Laryngol. 2005;114(4):253–257.
  • Giliberto JP, Dibildox D, Merati A. Unilateral Laryngoscopic findings associated with response to gabapentin in patients with chronic cough. JAMA Otolaryngol Head Neck Surg. 2017 Nov 1;143(11):1081–1085.
  • Shaffer M, Litts JK, Nauman E, et al. Speech-language pathology as a primary treatment for exercise-induced laryngeal obstruction. Immunol Allergy Clin North Am. 2018;38(2):293–302.
  • Vertigan AE, Haines J, Slovarp L. An update on speech pathology management of chronic refractory cough. J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6): 1756–1761.
  • Smyrnios NA, Irwin RS, Curley FJ. Chronic cough with a history of excessive sputum production. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Chest. 1995 Oct;108(4):991–997.
  • Kantar A, Chang AB, Shields MD, et al. ERS statement on protracted bacterial bronchitis in children. Eur Respir J. 2017;50(2):1602139.
  • Wurzel DF, Marchant JM, Yerkovich ST, et al. Protracted bacterial bronchitis in children: natural history and risk factors for bronchiectasis. Chest. 2016 Nov;150(5):1101–1108.
  • Martin MJ, Lee H, Clayton C, et al. Idiopathic chronic productive cough and response to open-label macrolide therapy: an observational study. Respirology. 2019 Jun;24(6):558–565.
  • Chung KF, McGarvey L, Mazzone SB. Chronic cough as a neuropathic disorder. Lancet Respir Med. 2013;1(5):414–422.
  • Fowles HE, Rowland T, Wright C, et al. Tussive challenge with ATP and AMP: does it reveal cough hypersensitivity? Eur Respir J. 2017;49(2):1601452.
  • Chang AB, Oppenheimer JJ, Weinberger M, et al. Etiologies of chronic cough in pediatric cohorts: CHEST guideline and expert panel report. Chest. 2017 Sep;152(3):607–617.
  • Weinberger M, Lockshin B. When is cough functional, and how should it be treated? Breathe. 2017;13(1):22–30.
  • Weinberger M. The habit cough: diagnosis and treatment. Pediatr Pulmonol. 2018 May;53(5):535–537.
  • De Marco R, Bugiani M, Cazzoletti L, et al. The control of asthma in Italy. A multicentre descriptive study on young adults with doctor diagnosed current asthma. Allergy. 2003;58(3):221–228.
  • de Marco R, Marcon A, Jarvis D, et al. Prognostic factors of asthma severity: a 9-year international prospective cohort study. J Allergy Clin Immunol. 2006 Jun;117(6):1249–1256.
  • Mincheva R, Ekerljung L, Bjerg A, et al. Frequent cough in unsatisfactory controlled asthma–results from the population-based West Sweden Asthma study. Respir Res. 2014 Aug;18(15):79.
  • Juniper EF, O’Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999 Oct;14(4):902–907.
  • Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004 Jan;113(1):59–65.
  • Song WJ, Lee JH, Kang Y, et al. Future risks in patients with severe asthma. Allergy Asthma Immunol Res. 2019;Nov;11(6):763–778.
  • Natarajan S, Free RC, Bradding P, et al. The relationship between the Leicester cough questionnaire, eosinophilic airway inflammation and asthma patient related outcomes in severe adult asthma. Respir Res. 2017;18(1):44.
  • Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009 Mar 5;360(10):973–984.
  • Brightling CE. Cough due to asthma and nonasthmatic eosinophilic bronchitis. Lung. 2010;188(1):13–17.
  • Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017 Aug 12;390(10095):659–668.
  • Birrell MA, Belvisi MG, Grace M, et al. TRPA1 agonists evoke coughing in guinea pig and human volunteers. Am J Respir Crit Care Med. 2009 Dec 1;180(11):1042–1047.
  • Smith J, Owen E, Earis J, et al. Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2006 Apr;117(4):831–835.
  • Garudadri S, Woodruff PG. Targeting chronic obstructive pulmonary disease phenotypes, endotypes, and biomarkers. Ann Am Thorac Soc. 2018 Dec;15(Suppl 4):S234–S238.
  • Ryerson CJ, Abbritti M, Ley B, et al. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology. 2011 Aug;16(6):969–975.
  • van Manen MJ, Birring SS, Vancheri C, et al. Cough in idiopathic pulmonary fibrosis. Eur Respir Rev. 2016 Sep;25(141):278–286.
  • Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med. 2012 Sep 18;157(6):398–406.
  • Azuma A, Taguchi Y, Ogura T, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res. 2011;12(1):143.
  • Wijsenbeek MS, Grutters JC, Wuyts WA. Early experience of pirfinidone in daily clinical practice in belgium and The netherlands: a retrospective cohort analysis. Adv Ther. 2015;32:691-704.
  • McGovern AE, Short KR, Kywe Moe AA, et al. Translational review: neuroimmune mechanisms in cough and emerging therapeutic targets. J Allergy Clin Immunol. 2018 Nov;142(5):1392–1402.
  • Smith J, Allman D, Badri H, et al. The neurokinin-1 receptor antagonist orvepitant is a novel antitussive therapy for chronic refractory cough: results from a phase 2 pilot study (VOLCANO-1). Chest. 2019.
  • Khalid S, Murdoch R, Newlands A, et al. Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: a double-blind randomized controlled trial. J Allergy Clin Immunol. 2014;134(1):56–62. e4.
  • Belvisi MG, Birrell MA, Wortley MA, et al. XEN-D0501, a novel transient receptor potential vanilloid 1 antagonist, does not reduce cough in patients with refractory cough. Am J Respir Crit Care Med. 2017;196(10):1255–1263.
  • Morice AH. TRPA1 receptors in chronic cough. Pulm Pharmacol Ther. 2017 Dec;47:42–44.
  • McGarvey L, Gibson PG. What is chronic cough? Terminology. J Allergy Clin Immunol Pract. 2019;7:1711–1714.
  • McGarvey L, Dupont L, Birring SS, et al. New understanding in the treatment of cough (NEUROCOUGH) ERS clinical research collaboration: improving care and treatment for patients with cough. Eur Respir J. 2019;53(5):May.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.